E. David Crawford, MD

E. David Crawford, MD

Editor-in-Chief
Grand Rounds in Urology
Professor of Urology
University of California, San Diego

San Diego, California

E. David Crawford, MD, is an internationally renowned urologist and an expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has authored many scientific articles, as well as textbook and book chapters. He is an editorial reviewer or consultant for many publications, including Urology, the Journal of Urology, and the Journal of Clinical Oncology. Dr. Crawford is a member of many organizations, including the American Society of Clinical Oncology (ASCO), the American Urological Association (AUA), and the American Association for the Advancement of Science (AAAS). He is the Founder and Chairman of the Prostate Conditions Education Council, which is responsible for raising awareness and screening millions of men for prostate health issues. He has received many awards, including the CaP Cure Annual Award for Scientific Presentation, and has twice been presented with a “Freddie Award” for best medical documentary. He has long been recognized as one of the Best Doctors of America, and is recognized by Men’s Health Magazine as one of the top 20 urologists for men in the country.

Articles by E. David Crawford, MD

RADAR III: Next Generation Imaging

E. David Crawford, MD, reviews the findings and recommendations from the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) III working group, and how its prior iterations, RADAR I and II, provided the rationale for the RADAR III manuscript. He discusses the next generation imaging modalities and radiotracers covered in RADAR III, as well as the group’s consensus on how they should be implemented in the evaluation of patients with prostate cancer.

Read More

Screening for Prostate Cancer: PSA: Why 1.5 is the New 4.0

E. David Crawford, MD, argues for using PSA levels of 1.5 ng/mL as the cutoff point for determining prostate cancer risk in routine screening. He discusses the need for utilizing better risk-assessment methods for detecting prostate cancer, such as genomic markers, in order to reduce unnecessary biopsies, over-detection of indolent disease, and reliance on PSA testing alone.

Read More

The Use of Genomic Markers and Prostate Biopsy Decisions

E. David Crawford, MD, discusses the concept of disruptive technologies—developments which displace established technology or create entirely new industries—in the context of prostate cancer treatment and diagnosis. He reviews new and developing technologies transforming prostate cancer care, and discusses how they can be constructive as well as destructive.

Read More

Join the GRU Community

- Why Join? -